Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 7:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 150 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Mouth-only breathing Clear all
Completed Not applicable Interventional

A Pilot Study Swiftsure

NCT05578599
View directory record Official record
Conditions
Ventilated Patients
Interventions
Swiftsure CCS device
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Sep 19, 2026, 7:36 PM EDT
Completed Early Phase 1 Interventional

Value of Ondansetron Medication vs Inhaled Isopropyl Therapy in the Emergency Department (VOMIITED)

NCT03125811
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Inhaled Isopropyl Alcohol (IPA), Oral Dissolvable Tablet Zofran (ondansetron)
Other · Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 19, 2026, 7:36 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Study Evaluating Safety and Pharmacokinetics of ASY202 in Adults With Asthma

NCT07665892
View directory record Official record
Conditions
Safety in Asthma Patients
Interventions
ASY202, Placebo
Combination Product
Lead sponsor
Aspeya, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Glendale, Arizona • Anaheim, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 19, 2026, 7:36 PM EDT
Completed Phase 2 Interventional Results available

Inorganic Nitrite to Amplify the Benefits and Tolerability of Exercise Training in Heart Failure With Preserved Ejection Fraction (HFpEF) (INABLE-Training)

NCT02713126
View directory record Official record
Conditions
Heart Failure
Interventions
Placebo, Sodium Nitrite, Accelerometer, Cardiac Exercise Training
Drug · Device · Other
Lead sponsor
Barry Borlaug
Other
Eligibility
40 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 19, 2026, 7:36 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes

NCT00332488
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Technosphere Insulin, Metformin & Secretagogues, Technosphere Insulin & Metformin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Sep 19, 2026, 7:36 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Non-Invasive Bioelectronic Analytics

NCT04100486
View directory record Official record
Conditions
Autonomic Dysfunction, Autonomic Imbalance, Autonomic Nervous System Diseases, Vagus Nerve Autonomic Disorder
Interventions
Standing-Squatting-Standing Test, Deep Breathing Test, Cold Pressor Test, Cold Face Test, Valsalva Maneuver, Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
Other · Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 19, 2026, 7:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets

NCT02812394
View directory record Official record
Conditions
Parkinson Disease
Interventions
CVT-301 (Dose Level 1), CVT-301 (Dose Level 2), Sinemet®
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
25 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 19, 2026, 7:36 PM EDT
Recruiting No phase listed Observational

Respiration From Pleth Validation

NCT07449715
View directory record Official record
Conditions
Respiratory Rate Monitoring
Interventions
Physiological Monitoring with SpO₂ Sensors and Capnography
Device
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
4 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 19, 2026, 7:36 PM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy

NCT01125748
View directory record Official record
Conditions
Allergic Asthma
Interventions
Omalizumab, Placebo, Asthma therapies
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
17 Years to 70 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
100
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Bakersfield, California + 87 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 19, 2026, 7:36 PM EDT
Not yet recruiting Not applicable Interventional

Pilot Study of the Sage Guard for Oral Cavity Protection

NCT07806812
View directory record Official record
Conditions
Intubated Patients
Interventions
Sage Guard oral protection device
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
13 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 19, 2026, 7:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

NCT05830071
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
CHF5993, CHF5259, Moxifloxacin 400mg, CHF5993 Placebo
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Sep 19, 2026, 7:36 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy Participants

NCT05755932
View directory record Official record
Conditions
Mucociliary Clearance
Interventions
HFO-1234ze(E), HFA-134a
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Kansas City, Kansas • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 19, 2026, 7:36 PM EDT
Recruiting No phase listed Observational

Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside

NCT05245903
View directory record Official record
Conditions
Alzheimer Disease, Dementia Alzheimers, Dementia, Cognitive Impairment, Mild Cognitive Impairment, Neurodegenerative Diseases, Neurocognitive Disorders, Neurocognitive Dysfunction, Cognitive Dysfunction, Mental Disorder
Interventions
Emerald Device Monitoring
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 19, 2026, 7:36 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Impact of Continuous Positive Airway Pressure on Breathing Motion Amplitude

NCT02852473
View directory record Official record
Conditions
Cancer
Interventions
Continuous Positive Airway Pressure
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Sep 19, 2026, 7:36 PM EDT
Completed Phase 3 Interventional Results available

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma

NCT00139659
View directory record Official record
Conditions
Asthma, Diabetes Mellitus
Interventions
Inhaled Insulin, Subcutaneous Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 77 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
86
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2010 · Synced Sep 19, 2026, 7:36 PM EDT
Completed Phase 2Phase 3 Interventional Results available

26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00463567
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
Interventions
Indacaterol, Formoterol (12 µg b.i.d.), Tiotropium (18 µg o.d.), Placebo to Indacaterol, Placebo to Formoterol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
2,059 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
221
States / cities
Anniston, Alabama • Birmingham, Alabama • Homewood, Alabama + 163 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Sep 19, 2026, 7:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy Volunteers

NCT04570644
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease
Interventions
ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)
Drug
Lead sponsor
AZTherapies, Inc.
Industry
Eligibility
55 Years to 79 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 19, 2026, 7:36 PM EDT
Completed Phase 3 Interventional Results available

Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

NCT01165138
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder, Placebo Inhaltion Powder
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Bell Gardens, California • Huntington Beach, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 19, 2026, 7:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects

NCT02648438
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
AZD7594 Solution for infusion (150 μg intravenous formulation), AZD7594 Oral suspension (1200 μg oral formulation), AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler), AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler), AZD7594 Pressurized inhalation suspension (400 μg) by pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Sep 19, 2026, 7:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation

NCT05091723
View directory record Official record
Conditions
Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)
Interventions
Nezulcitinib (TD-0903) Dose A, Nezulcitinib (TD-0903) Dose B
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Sep 19, 2026, 7:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers

NCT04461353
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Aerolized Hydroxychloroquine Sulfate, Placebo
Drug · Other
Lead sponsor
Pulmoquine Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 19, 2026, 7:36 PM EDT
Completed Not applicable Interventional Results available

Vitabreath Pilot in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT03349437
View directory record Official record
Conditions
COPD, Dyspnea
Interventions
Vitabreath Device, Pursed Lip Breathing
Device · Other
Lead sponsor
Philips Respironics
Industry
Eligibility
40 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Youngstown, Ohio • Jefferson Hills, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 19, 2026, 7:36 PM EDT
Completed No phase listed Observational

Oral and Swallowing Function in Older Adults

NCT06368830
View directory record Official record
Conditions
Oropharyngeal Dysphagia
Interventions
3-ounce water swallow test, Kayser-Jones Brief Oral Health Status Examination (BOHSE), Tongue pressure, Test of Masticating and Swallowing Solids (TOMASS), Respiratory function tests
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
60 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 19, 2026, 7:36 PM EDT
Recruiting No phase listed Observational

Forced Oscillometry in Infants With Bronchopulmonary Dysplasia

NCT04270045
View directory record Official record
Conditions
Infant, Premature, Diseases, Bronchopulmonary Dysplasia, Respiratory Distress Syndrome
Interventions
Non-invasive forced airway oscillometry
Device
Lead sponsor
Winston Manimtim
Other
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 19, 2026, 7:36 PM EDT